WO2002085847A3 - Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyle] et ses applications - Google Patents

Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyle] et ses applications Download PDF

Info

Publication number
WO2002085847A3
WO2002085847A3 PCT/EP2002/002598 EP0202598W WO02085847A3 WO 2002085847 A3 WO2002085847 A3 WO 2002085847A3 EP 0202598 W EP0202598 W EP 0202598W WO 02085847 A3 WO02085847 A3 WO 02085847A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrosothio
valyl
glutamyl
glycine
gamma
Prior art date
Application number
PCT/EP2002/002598
Other languages
English (en)
Other versions
WO2002085847A2 (fr
Inventor
Moliner Jose Repolles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Original Assignee
Lacer Sa
Moliner Jose Repolles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer Sa, Moliner Jose Repolles, Perez-Rasilla Eduardo Salas, Coy Francisco Pubill filed Critical Lacer Sa
Priority to AU2002310939A priority Critical patent/AU2002310939A1/en
Publication of WO2002085847A2 publication Critical patent/WO2002085847A2/fr
Publication of WO2002085847A3 publication Critical patent/WO2002085847A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un glycine, N-[N-L-η-glutamyl-3-(nitrosothio)-L-valyle] ayant la formule suivante (I) et ses sels pharmaceutiquement acceptables ainsi que les compositions pharmaceutiques renfermant un ou plusieurs de ces composés, les méthodes de traitement et de prévention de maladies consistant à administrer une quantité efficace d'un ou plusieurs de ces composés et l'application d'un ou plusieurs de ces composés dans la fabrication d'une composition pharmaceutique pour le traitement et la prévention de maladies.
PCT/EP2002/002598 2001-03-13 2002-03-08 Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyle] et ses applications WO2002085847A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002310939A AU2002310939A1 (en) 2001-03-13 2002-03-08 Glycine, n-(n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl) and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100577 2001-03-13
ES200100577A ES2173044B1 (es) 2001-03-13 2001-03-13 Derivados de glicina, n-(n-l-gamma-glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.

Publications (2)

Publication Number Publication Date
WO2002085847A2 WO2002085847A2 (fr) 2002-10-31
WO2002085847A3 true WO2002085847A3 (fr) 2003-10-30

Family

ID=8497059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002598 WO2002085847A2 (fr) 2001-03-13 2002-03-08 Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyle] et ses applications

Country Status (5)

Country Link
AU (1) AU2002310939A1 (fr)
ES (1) ES2173044B1 (fr)
PA (1) PA8541201A1 (fr)
PE (1) PE20021040A1 (fr)
WO (1) WO2002085847A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (fr) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Dérivés nitrosolthiol, leur préparation et utilisation
WO2000044714A1 (fr) * 1999-01-27 2000-08-03 Lacer, S.A. S-nitrosothiols en tant qu'agents pour le traitement de troubles circulatoires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (fr) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Dérivés nitrosolthiol, leur préparation et utilisation
WO2000044714A1 (fr) * 1999-01-27 2000-08-03 Lacer, S.A. S-nitrosothiols en tant qu'agents pour le traitement de troubles circulatoires
EP1157987A1 (fr) * 1999-01-27 2001-11-28 Lacer, S.A. S-nitrosothiols en tant qu'agents pour le traitement de troubles circulatoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASKEW S C ET AL: "Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione.", BIOORGANIC & MEDICINAL CHEMISTRY. ENGLAND JAN 1995, vol. 3, no. 1, January 1995 (1995-01-01), pages 1 - 9, XP002225525, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
ES2173044B1 (es) 2004-01-16
ES2173044A1 (es) 2002-10-01
PE20021040A1 (es) 2002-11-19
WO2002085847A2 (fr) 2002-10-31
AU2002310939A1 (en) 2002-11-05
PA8541201A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
CA2427227A1 (fr) Compose de lactam
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
WO2004037807A3 (fr) Composes medicinaux
WO2006133941A3 (fr) Ingredient pharmaceutique actif a base de cannabinoides pour formes posologiques ameliorees
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
WO2005037798A3 (fr) Nouveaux composés
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
WO2005030753A3 (fr) Agents therapeutiques utiles pour traiter la douleur
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002062322A3 (fr) Glycine-betaine et utilisation correspondante
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2003051838A3 (fr) Inhibiteurs de la proteine kinase
WO2002064552A8 (fr) DERIVE DE α-AMINO-N-HYDROXY-ACETAMIDE
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2000066550A8 (fr) Nouveaux composes
BE2016C017I2 (fr)
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP